PharmaSaga to Compete for the Startup Pitch Competition Championship at BIO North America.

The US BIO International Convention is a major event in the global biotechnology and pharmaceutical sectors, bringing together top-tier pharmaceutical companies, biotech startups, and investors from around the world. The convention provides extensive opportunities for business collaboration, particularly in areas such as licensing, technology transfer, and clinical partnerships.

The main goal of our participation in this exhibition is to engage with the top ten international pharmaceutical companies in the diabetes field.

Our core product, the diabetes drug PS1, is an innovative therapy with first-in-class potential. It works by inhibiting PDIA4, reducing ROS (Reactive Oxygen Species), and keeping pancreatic islet cells alive and functional. We have extensively discussed this potential with the top ten and other international pharmaceutical companies both before and after the conference. This exhibition will be a crucial opportunity for both parties to hold further face-to-face negotiations.

Furthermore, we are deeply honored to have been selected again for the Start-up Stadium, a competition specifically designed for global biotech startups to discover companies with groundbreaking and innovative technologies. Among the 57 selected teams worldwide, we are one of only two teams from Asia. 

We competed for the world championship on June 17th. This not only serves as recognition of our technology but also provides us with increased exposure and opportunities for collaboration.